# Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)

> **NCT00843986** · PHASE3 · TERMINATED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Hyponatremia
- Acute Decompensated Heart Failure

## Interventions

- **DRUG:** conivaptan
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00843986
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The clinical study has been terminated based on difficulties to enroll eligible subjects per protocol inclusion and exclusion criteria.
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00843986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00843986, "Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00843986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*